Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab rechallenge in previously treated advanced non-small cell lung cancer
2017-003947-39Phase 2Active
- Sponsor
- Fundación GECP
- Start
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Overall response rate. Started Apr 2018; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-003947-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003947-39.